FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Nuvation takes the battle to Nuvalent
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
Adcetris gives Pfizer its first post-Seagen surprise
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Pfizer isn’t done with CD47
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
